[Melagatran and ximelagatran. Pharmacologic characteristics and anesthesiological aspects].
Melagatran is a direct inhibitor of thrombin and-like its oral prodrug ximelagatran-a newly developed dipetide with high antithrombotic efficacy. They present a linear dose-response, a short plasma half-life and the therapeutic range may be advantageous compared with classic anticoagulants such as heparins or vitamin K antagonists. The results of clinical studies for prevention and treatment of thromboembolic complications are encouraging. The use of melagatran and ximelagatran will gain significance in the perioperative management, thus being of particular importance for anaesthesiology and critical care medicine in the near future.
Pindur
G
G
Abteilung für Klinische Hämostaseologie und Transfusionsmedizin, Universitätskliniken des Saarlandes, Homburg/Saar.
Ziegeler
S
S
Kleinschmidt
S
S
D000758:Anesthesia; D000818:Animals; D001384:Azetidines / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D001596:Benzylamines; D004305:Dose-Response Relationship, Drug; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D005998:Glycine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics / Q000494:pharmacology*; D006207:Half-Life; D006801:Humans
D001384:Azetidines; D001596:Benzylamines; D005343:Fibrinolytic Agents; C109573:melagatran; C426686:ximelagatran; D005998:Glycine